# Parametric Response Mapping (PRM) for the detection of chronic lung injury in hematopoietic cell transplant recipients

> **NIH NIH R01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $727,648

## Abstract

ABSTRACT
Chronic lung dysfunction (CLD) is a potentially severe complication of bone marrow transplantation (BMT),
particularly prevalent in patients who develop chronic graft versus host disease (GVHD) post-BMT. The
development of CLD is associated with a 20%-40% long term survival rate, with the majority of patients
diagnosed with CLD only after they have developed significant (and potentially irreversible) lung pathology.
There is a critical need to identify CLD earlier in its clinical course, at a stage when treatment may prove beneficial
to patients. Parametric response mapping (PRM) is a novel computed tomography (CT) based methodology that
when applied to standard CT scans is capable of identifying and quantifying a variety of lung disease subtypes
in patients. This technology was initially developed at Michigan Medicine over 10 years ago for patients with
chronic obstructive pulmonary disease (COPD). In both single center and multicenter trials, PRM has
demonstrated efficacy for the identification of CLD in adult BMT patients. Our central hypothesis is that PRM can
identify patients with chronic GVHD who are at high risk for the development of CLD. We propose an
observational study to examine PRM in adult and pediatric subjects (≥ 3 years in age) with chronic GVHD post-
BMT. To test our hypothesis, we have established 3 specific aims. In the first two, we will examine PRM values
at two main time points: at the onset of chronic GVHD (Aim 1) and at the onset of CLD (Aim 2), with CLD defined
by standard NIH criteria. In Aim 3, we will develop a machine learning model that will incorporate serologic and
pulmonary function test (PFT) biomarkers with PRM values to develop a composite biomarker strategy. Upon
completion of our current proposal, we will establish PRM as a predictor of CLD in adult BMT patients. In addition,
the PRM, PFT, and serologic data obtained from pediatric BMT patients will provide a data bank for future
research in this population. Historically, the ability to identify CLD in pediatric patients has been PFT-dependent,
with PFTs technically challenging to conduct in young children. The use of PRM as a diagnostic indicator of CLD
in pediatric BMT patients will be a major advance of this proposal. Finally, our proposal takes our PRM
methodology forward in adults, allowing us to study the trajectory of lung disease in adult BMT recipients with
chronic GVHD, and following the onset of CLD.

## Key facts

- **NIH application ID:** 10908593
- **Project number:** 5R01HL162661-03
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Craig J Galban
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $727,648
- **Award type:** 5
- **Project period:** 2022-08-15 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10908593

## Citation

> US National Institutes of Health, RePORTER application 10908593, Parametric Response Mapping (PRM) for the detection of chronic lung injury in hematopoietic cell transplant recipients (5R01HL162661-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10908593. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*